Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesoridazine and human sleep.

K Adam, S Allen, I Carruthers-Jones

    British Journal of Clinical Pharmacology
    |February 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Continuous non-invasive measurement of core vital signs in the hospital ward.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
    Same author

    Patient experience of an abstinence-based Indigenous residential treatment program in Northern Ontario: a descriptive qualitative study.

    Frontiers in health services·2025
    Same author

    Implementation and evaluation of a two-eyed seeing approach using traditional healing and seeking safety in an indigenous residential treatment program in Northern Ontario.

    International journal of circumpolar health·2022
    Same author

    Community trial evaluating the integration of Indigenous healing practices and a harm reduction approach with principles of seeking safety in an Indigenous residential treatment program in northern Ontario.

    BMC health services research·2022
    Same author

    American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting).

    Drugs of today (Barcelona, Spain : 1998)·2021
    Same author

    A study protocol for a quasi-experimental community trial evaluating the integration of indigenous healing practices and a harm reduction approach with principles of seeking safety in an indigenous residential treatment program in Northern Ontario.

    Harm reduction journal·2021
    Same journal

    N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

    British journal of clinical pharmacology·2026
    Same journal

    The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

    British journal of clinical pharmacology·2026
    Same journal

    Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

    British journal of clinical pharmacology·2026
    Same journal

    UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

    British journal of clinical pharmacology·2026
    See all related articles

    Mesoridazine, a short-acting hypnotic, improved sleep quality in older adults by reducing nighttime awakenings and increasing REM sleep. However, users reported decreased daytime energy and freshness upon waking.

    Area of Science:

    • Pharmacology
    • Sleep Medicine
    • Gerontology

    Background:

    • Mesoridazine, a phenothiazine, exhibits a short half-life and potential hypnotic properties.
    • Older adults represent a demographic often experiencing sleep disturbances.

    Purpose of the Study:

    • To investigate the effects of mesoridazine on polysomnographic sleep parameters and subjective sleep quality in late middle-aged volunteers.
    • To assess potential withdrawal effects following mesoridazine administration.

    Main Methods:

    • Polysomnographic all-night sleep recordings were conducted on seven subjects over a 7-week period, including a 3-week mesoridazine (10 mg nightly) treatment phase.
    • Subjective self-ratings of sleep quality, daytime concentration, and anxiety were assessed in sixteen subjects over a 6-week study.

    Related Experiment Videos

    Main Results:

    • Mesoridazine reduced transitions to wakefulness and Stage 1 sleep, decreasing time spent in Stage 1 sleep.
    • The drug increased REM sleep, with a subsequent rebound decrease upon withdrawal. Slow-wave sleep (Stages 3+4) remained unaltered.
    • Subjectively, sleep quality improved, but participants reported diminished zest and freshness post-awakening. Daytime concentration and anxiety were unaffected.

    Conclusions:

    • Mesoridazine at 10 mg nightly demonstrates hypnotic effects in older adults, altering sleep architecture by reducing lighter sleep stages and increasing REM sleep.
    • While improving subjective sleep quality, mesoridazine may lead to transient morning grogginess and reduced daytime vigor.
    • Further research is warranted to explore the long-term efficacy and side effect profile of mesoridazine as a hypnotic agent in geriatric populations.